Results 61 to 70 of about 23,043 (148)

Leveraging paired germline and somatic analysis to improve the classification of DDX41 variants

British Journal of Haematology, Volume 208, Issue 5, Page 1584-1595, May 2026.
Summary Constitutional pathogenic variants in DDX41 predispose to myelodysplasia and acute myeloid leukaemia. Acquisition of subsequent somatic hits in the second allele is frequent, with notable recurrent variants at key hotspots. Sequencing of Deoxyribonucleic acid from blood/marrow of 239 patients with suspected/confirmed haematological malignancies
Andrew George, Elisabeth Rolf, Monika Domeradzka, Sara Ribeiro, Brittany Mills, April Hallett, Suzanne Macmahon, Paula Proszek, Ridwan Shaikh, Lina Yuan, Michael Hubank, Mikel Valganon Petrizan, Terri P. McVeigh, Jamshid S. Khorashad   +13 more
wiley   +1 more source

Polycythemia Vera and Essential Thrombocythemia: A Nationwide Population‐Based Study on Treatment Patterns, Vascular Complications and Survival

European Journal of Haematology, Volume 116, Issue 5, Page 545-557, May 2026.
ABSTRACT Background Polycythemia vera (PV) and essential thrombocythemia (ET) are associated with a well‐recognized increased risk of thrombotic events, bleeding, and all‐cause mortality, but the frequency of these outcomes during treatment has rarely been assessed in large cohorts.
Anneli Enblom Larsson, Henrik Renlund, Björn Andréasson, Henrik Holmberg, Maria Liljeholm, Anders Själander   +5 more
wiley   +1 more source

Myeloproliferative disorders and their effects on bone homeostasis: the role of megakaryocytes.

Blood, 2022
Karagianni A, Ravid K.
europepmc   +1 more source

Generalized Chorea and JAK2V617F Mutation-Positive Myeloproliferative Disorders. [PDF]

Mov Disord Clin Pract, 2020
Betté S, Moore H.
europepmc   +1 more source

COVID-19 in Philadelphia-negative myeloproliferative disorders: a GIMEMA survey. [PDF]

Leukemia, 2020
Breccia M, Piciocchi A, De Stefano V, Finazzi G, Iurlo A, Fazi P, Soddu S, Martino B, Palandri F, Siragusa S, Albano F, Passamonti F, Vignetti M, Vannucchi AM.   +13 more
europepmc   +1 more source

Screening for precapillary pulmonary hypertension in chronic myeloproliferative disorders: the role of N-terminal pro-B-type natriuretic peptide and vascular endothelial growth factor - a pilot study. [PDF]

Arch Med Sci, 2021
Költő G, Tőkés-Füzesi M, Papp E, Adravetz Z, Komócsi A, Egyed M, Faludi R.   +6 more
europepmc   +1 more source

Analytical cohort study on splenomegaly and cytopenias in myeloproliferative disorders. [PDF]

Bioinformation
Sinha S, Rajan VP, Nair AU, Jakka AP, Chandrasekaran SP.   +4 more
europepmc   +1 more source

Clinical course and short-term outcome of postsplenectomy reactive thrombocytosis in children without myeloproliferative disorders: A single institutional experience from a developing country. [PDF]

PLoS One, 2020
Zvizdic Z, Kovacevic A, Milisic E, Jonuzi A, Vranic S.   +4 more
europepmc   +1 more source

Pediatric Pulmonary Hypertension Associated With Treatment of Myeloproliferative Disorders and Malignant Tumors. [PDF]

Pulm Circ
Chida-Nagai A, Terashita Y, Hirabayashi S, Yamazawa H, Cho Y, Manabe A.   +5 more
europepmc   +1 more source

SFX-01 is therapeutic against myeloproliferative disorders caused by activating mutations in Shp2. [PDF]

EMBO Mol Med
Cho HJ, Smith J, Switzer CH, Louka E, Charles RL, Prysyazhna O, Schroder E, Fernandez-Caggiano M, de Jesus DS, Eminaga S, Yin X, Yang X, Lynham S, Mayr M, Morales V, Bianchi K, Rajeeve V, Cutillas PR, Mead AJ, Eaton P.   +19 more
europepmc   +1 more source